April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Detecting Novel Biomarkers in Ocular Vogt-Koyanagi-Harada Syndrome Using SELDI-TOF-MS
Author Affiliations & Notes
  • R. M. Gilbert
    Ophthalmology and Medical Microbiology, University of Liverpool, Liverpool, United Kingdom
    Ocular Pathology,
    McGill University, Montreal, Quebec, Canada
  • J. Isenberg
    McGill University, Montreal, Quebec, Canada
  • B. F. Fernandes
    Ocular Pathology,
    McGill University, Montreal, Quebec, Canada
  • M. Ndao
    National Reference Laboratory for Parasitology, Montreal General Hospital, Montreal, Quebec, Canada
  • R. N. Belfort
    Oftalmologia, McGill University - UNIFESP, Montreal, Quebec, Canada
  • M. N. Burnier
    McGill University, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships  R.M. Gilbert, None; J. Isenberg, None; B.F. Fernandes, None; M. Ndao, None; R.N. Belfort, None; M.N. Burnier, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4849. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. M. Gilbert, J. Isenberg, B. F. Fernandes, M. Ndao, R. N. Belfort, M. N. Burnier; Detecting Novel Biomarkers in Ocular Vogt-Koyanagi-Harada Syndrome Using SELDI-TOF-MS. Invest. Ophthalmol. Vis. Sci. 2010;51(13):4849.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Vogt-Koyanagi-Harada Syndrome (VKH) is a multisystem autoimmune disorder directed against antigens present, or associated with melanocytes. The ocular manifestations are characterized by a bilateral granulomatous panuveitis, which may lead to exudative retinal detachment. The diagnosis of VKH is often difficult and relies on a combination of clinical signs, laboratory tests and imaging. There is currently no single diagnostic blood test for VKH and, to date, no known biomarkers specific for VKH. The purpose of this study is to analyze protein patterns in the blood serum of patients with ocular Vogt-Koyanagi-Harada syndrome (VKH) in comparison to non-VKH control patients, in order to identify potential protein biomarkers for VKH.

Methods: : Blood serum samples were collected from 3 patients with VKH and 9 non-VKH control patients (no history of uveitis, toxoplasma IgG negative). These samples were used for protein profiling by surface enhanced laser desorption/ ionization-time of flight mass spectrometry (SELDI-TOF-MS). Data analysis was performed using Biomarker Pattern software, which incorporates multivariate statistics and decision tree-based classification.

Results: : Analysis of the twelve blood serum samples using SELDI-TOF-MS, identified ten peptide fragments that were significantly upregulated (p<0.05) in the VKH group. Of these peptide fragments, one peptide (44.7kDa), showed increased ability to discriminate VKH from non-VKH controls, following multivariate analysis, with a sensitivity of 100% and a specificity of 90%.

Conclusions: : In this pilot study, comparison of blood serum from patients with VKH and non-VKH controls revealed some differences in protein profiles using SELDI-TOF-MS. Furthermore, following statistical analysis, a single peptide fragment (44.7kDa) was identified, which distinguished VKH from non-VKH patients with a high sensitivity and specificity. As no biomarker for VKH exists currently, this study demonstrates the potential for SELDI-TOF-MS technology to identify novel biomarkers for VKH.

Keywords: anterior segment 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.